
|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series

Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus
2
Measles Update: February 6, 2026
3
Antibiotics Deconstructed: IV Fosfomycin
4
HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives
5



















































































































































